Gliknik enters licensing agreement with Pfizer

30 September 2013

US privately-held biopharmaceutical company Gliknik has entered into an exclusive worldwide licensing agreement with US pharma giant Pfizer (NYSE: PFE) for GL-2045, which is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). The market for IVIG is expected to be worth about $7 billion in 2013, Gliknik noted.

Under the terms of the deal, Pfizer will receive an exclusive worldwide license to GL-2045 for all therapeutic indications. In return, Gliknik will get an upfront of $25 million and is eligible for development, regulatory and commercial milestone payments. Gliknik is also eligible for tiered, double-digit royalties on net sales of any products that are commercialized under this accord.

GL-2045 has shown promise in preclinical tests

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK